Search results for: 'Engineered Antibody Therapeutics for Cancer'

23 Jun 2023  |  Global  |  Market Research

Global Tissue-engineered Skin Substitute Growth Opportunities

Breakthrough Technologies and Competitive Intensity Drive Innovation

Infographics

×

Rising incidents of burn injuries, road accidents, and other trauma injuries, along with increasing cases of chronic wounds, such as diabetic ulcers and venous ulcers, are boosting the global tissue-engineered skin substitutes (TESS) market. Moreover, the increasing number of surgical injuries, plastic surgeries, cosmetic surgeries, and other recon...

This research service focuses on the market for such therapeutics. It aims to introduce market opportunity for breast cancer therapeutics in the United States, and the top seven markets in Europe (Germany, France, the United Kingdom, Spain, Italy, Benelux and Scandinavia). For the purpose of analysis, a market forecast for the total world breast ca...

The U.S. Therapeutic Monoclonal Antibodies Markets is a evolving market undergoing many changes. This research service includes in depth analysis of the total market as well as the various therapeutic classes for which monoclonal antibodies are available. This analysis includes revenue forecasts, product/pipeline analysis, and strategic perspective...

The Global Cancer Therapeutics Market is a fast growing market that is relying heavily on new drugs. The total therapeutic market is expected to grow from $23.1 billion in 2004 to $60.6 billion in 2011. The targeted therapy segment is providing the growth of the entire market with an expected compound annual growth rate of 24.1 percent for 2004-2...

This research service explores the market for therapeutics used for the treatment of breast cancer in the Unites States of America. It analyzes the various challenges faced by pharmaceutical companies, and the competitive advantages and disadvantages of their products in the market.

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...

This study explores the transformative potential of organoid technologies in advancing cancer research, precision medicine, and drug discovery. Organoids—3D cell culture systems derived from patient tumors—preserve tumor heterogeneity and provide physiologically relevant models for studying cancer biology, therapeutic response, and resistance mecha...

Software-defined vehicle (SDV) development is reshaping Europe’s automotive engineering service provider (ESP) market, shifting demand from capacity-led engineering support toward platform integration, software lifecycle management, validation automation, and compliance-by-design. This Frost & Sullivan analysis assesses how original equipment manuf...

Emerging Therapeutics in the U.S. Colorectal Cancer Market is a rapidly progressing field that is set to generate over $2 billion in revenue in the coming years. The market has witnessed unprecedented growth with the launch of a new segment and as a result competition has increased in the cytotoxic market. The dynamics of this market are changing...